Evidence map›Paper›PMID 34433869›Full record

ArticleScientific reports2021

Comparison of seven single cell whole genome amplification commercial kits using targeted sequencing.

Tamir Biezuner, Ofir Raz, Shiran Amir, Lilach Milo, Rivka Adar, Yael Fried, Elena Ainbinder, Ehud Shapiro

Abstract readComparative Study
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Recent Advances in Methods for Circulating Tumor Cell Detection.International journal of molecular sciences · 2023
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tamir BiezunerDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, 234 Herzl Street, 7610001, Rehovot, Israel. Tamir.Biezuner@weizmann.ac.il.ORCID 0000-0002-3642-0977
Ofir RazDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, 234 Herzl Street, 7610001, Rehovot, Israel.
Shiran AmirDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, 234 Herzl Street, 7610001, Rehovot, Israel.
Lilach MiloDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, 234 Herzl Street, 7610001, Rehovot, Israel.
Rivka AdarDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, 234 Herzl Street, 7610001, Rehovot, Israel.
Yael FriedStem Cell Core and Advanced Cell Technologies, Life Sciences Core Facilities, Weizmann Institute of Science, 761001, Rehovot, Israel.
Elena AinbinderStem Cell Core and Advanced Cell Technologies, Life Sciences Core Facilities, Weizmann Institute of Science, 761001, Rehovot, Israel.
Ehud ShapiroDepartment of Computer Science and Applied Mathematics, Weizmann Institute of Science, 234 Herzl Street, 7610001, Rehovot, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in whole genome amplification (WGA) techniques enable understanding of the genomic sequence at a single cell level. Demand for single cell dedicated WGA kits (scWGA) has led to the development of several commercial kit. To this point, no robust comparison of all available kits was performed. Here, we benchmark an economical assay, comparing all commercially available scWGA kits. Our comparison is based on targeted sequencing of thousands of genomic loci, including highly mutable regions, from a large cohort of human single cells. Using this approach we have demonstrated the superiority of Ampli1 in genome coverage and of RepliG in reduced error rate. In summary, we show that no single kit is optimal across all categories, highlighting the need for a dedicated kit selection in accordance with experimental requirements.

Indexed as

Cells, CulturedHumansPolymerase Chain ReactionSensitivity and SpecificitySingle-Cell AnalysisWhole Genome Sequencing

Identifiers

PMID34433869
PMCPMC8387353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.